Tissue-level evidence in clinical specimens offers insight into the role of TGFβ in joint disease, and transgenic mouse models of joint disease with a tissue-specific ablation of key receptors or effectors within the TGFβ signaling pathway provide powerful tools for isolating the tissue- or cell-type–specific functions of TGFβ in joint disease. This evidence concerns the gene TGFB1 and arthropathy.